- Home
- CNDT vs ERAS Comparison
CNDT vs ERAS Comparison
Compare CNDT & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNDT
- ERAS
- Stock Information
- Founded
- CNDT 2016
- ERAS 2018
- Country
- CNDT United States
- ERAS United States
- Employees
- CNDT N/A
- ERAS N/A
- Industry
- CNDT Business Services
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- CNDT Consumer Discretionary
- ERAS Health Care
- Exchange
- CNDT Nasdaq
- ERAS Nasdaq
- Market Cap
- CNDT 441.8M
- ERAS 484.4M
- IPO Year
- CNDT N/A
- ERAS 2021
- Fundamental
- Price
- CNDT $2.48
- ERAS $1.40
- Analyst Decision
- CNDT
- ERAS Strong Buy
- Analyst Count
- CNDT 0
- ERAS 6
- Target Price
- CNDT N/A
- ERAS $4.83
- AVG Volume (30 Days)
- CNDT 908.7K
- ERAS 779.4K
- Earning Date
- CNDT 08-06-2025
- ERAS 08-19-2025
- Dividend Yield
- CNDT N/A
- ERAS N/A
- EPS Growth
- CNDT N/A
- ERAS N/A
- EPS
- CNDT 0.06
- ERAS N/A
- Revenue
- CNDT $3,112,000,000.00
- ERAS N/A
- Revenue This Year
- CNDT N/A
- ERAS N/A
- Revenue Next Year
- CNDT $2.85
- ERAS N/A
- P/E Ratio
- CNDT $40.01
- ERAS N/A
- Revenue Growth
- CNDT N/A
- ERAS N/A
- 52 Week Low
- CNDT $1.90
- ERAS $1.01
- 52 Week High
- CNDT $4.90
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- CNDT 40.64
- ERAS 43.81
- Support Level
- CNDT $2.34
- ERAS $1.34
- Resistance Level
- CNDT $2.75
- ERAS $1.54
- Average True Range (ATR)
- CNDT 0.12
- ERAS 0.12
- MACD
- CNDT -0.03
- ERAS -0.02
- Stochastic Oscillator
- CNDT 27.45
- ERAS 12.77
About CNDT Conduent Incorporated
Conduent Inc acts as a provider of business process services with expertise in transaction-intensive processing, analytics, and automation. The company provides industry-focused service offerings in growth markets such as Healthcare and Transportation as well as provides multi-industry services such as transaction processing, customer care, and payment services. It operates through three segments namely Commercial Industries which is the key revenue-driving segment, Government Services, and Transportation. The group operates its business in the United States, Europe, and Other areas of which the majority of revenue is generated in the United States.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.